10-K - SAB Biotherapeutics, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

SAB Biotherapeutics, Inc. reported a net income of $13.3 million for fiscal year 2025, a significant improvement driven primarily by a $62.8 million non-cash gain from changes in the fair value of warrant liabilities. The company generated no revenue, with total operating expenses of $49.0 million, resulting in an operating loss of $49.0 million. Key financial activities included a $168.7 million private investment in public equity (PIPE) financing, which bolstered the balance sheet, ending the year with $56.6 million in cash and cash equivalents and total assets of $172.8 million. The company's cash flow from operations was negative $44.8 million, reflecting ongoing investment in research and development, which accounted for $34.4 million of operating expenses.

Key Takeaways

1Reported net income of $13.3M, driven by a $62.8M non-cash gain from warrant liability fair value changes.

2Generated zero revenue with total operating expenses of $49.0M, resulting in a $49.0M operating loss.

3Raised $168.7M through a PIPE financing, significantly strengthening the balance sheet.

4Ended the year with $56.6M in cash and cash equivalents and total assets of $172.8M.

5Research and development expenses were $34.4M, representing the largest component of operating costs.

Key Financial Metrics

EPS

$0.00

Basic income per common share: $0

Net Income

$13.3M